Calton & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

Calton & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-710	Closed	-$89K	–	1396
2017 Q4	$89K	Buy	+710	New	+$86.5K	0.02%	514

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Calton & Associates's ALXN Position: Q1 2018 in Review

Calton & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 710 shares — an estimated $89K sold.

Calton & Associates first reported a position in ALXN in Q4 2017 and held it in 1 quarter. The position peaked at $89K in Q4 2017. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

Calton & Associates reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 710 Alexion Pharmaceuticals shares in Q1 2018, an estimated $89K.
Calton & Associates first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Calton & Associates's Alexion Pharmaceuticals position peaked at $89K in Q4 2017.
596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.